Skip to content

Pharminent

Primary Menu
  • Home
    • Pro Hub
Light/Dark Button
Hub
  • Home
  • Clinical Data
  • Summit’s PD-1/VEGF to take center stage at ASCO, with wide impact for peers
  • Clinical Data

Summit’s PD-1/VEGF to take center stage at ASCO, with wide impact for peers

BioSpace

As Summit Therapeutics' Chinese partner prepares to reveal data for a key trial at ASCO, analysts consider the impact on rivals Merck, Bristol Myers Squibb and BioNTech.

Oncology

Read full story

pharminent May 29, 2026 (Last updated: May 29, 2026)

BioSpace

As Summit Therapeutics’ Chinese partner prepares to reveal data for a key trial at ASCO, analysts consider the impact on rivals Merck, Bristol Myers Squibb and BioNTech.

Oncology

Read full story

Post navigation

Previous: Replimune gives cancer immunotherapy a third try after FDA leadership shakeup
Next: ASCO: BMS hails “compelling” phase 3 celmod readout

Related Stories

  • Clinical Data

Novartis hit as Lp(a) drug fails cardio outcomes trial

pharminent September 7, 2026
  • Clinical Data

Major trial of Roche Alzheimer’s drug kicks off in Europe

pharminent September 7, 2026
  • Clinical Data

AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study

pharminent September 4, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.